Literature DB >> 19195498

Comparison of effects of rosuvastatin (10 mg) versus atorvastatin (40 mg) on rho kinase activity in caucasian men with a previous atherosclerotic event.

Ron Rawlings1, Anju Nohria, Ping-Yen Liu, Jason Donnelly, Mark A Creager, Peter Ganz, Andrew Selwyn, James K Liao.   

Abstract

In addition to inhibiting cholesterol biosynthesis, statins also inhibit the formation of isoprenoid intermediates, which are required for the activation of the Rho/Rho kinase (ROCK) pathway. Increased ROCK activity has been implicated in causing endothelial dysfunction and atherosclerosis. However, it is not known whether statins, at doses used to lower cholesterol levels, inhibit ROCK activity in humans with atherosclerosis. Furthermore, it is not known whether lipophilic and hydrophilic statins differ in their ability to inhibit ROCK activity. Accordingly, we enrolled 30 men with stable atherosclerosis (low-density lipoprotein [LDL] > or =100 mg/dL) in a randomized, double-blind study comparing equivalent LDL-lowering doses of a hydrophilic statin (rosuvastatin 10 mg once a day) with a lipophilic statin (atorvastatin 40 mg once a day) for 28 days. We assessed the change in lipids, ROCK activity, and flow-mediated dilation (FMD) of the brachial artery before and after statin therapy. Both treatment groups exhibited comparable 30% to 32% and 42% to 45% reductions in total and LDL cholesterol, respectively. Only atorvastatin reduced triglycerides, and neither statin altered high-density lipoprotein cholesterol. Whereas both statins inhibited ROCK activity (p <0.0001), the extent of inhibition was greater with rosuvastatin (18 +/- 2% vs 8 +/- 2%, p = 0.0006). Statins also improved FMD from 7.4 +/- 0.6 to 9.3 +/- 0.4 (p = 0.003) with rosuvastatin being slightly better than atorvastatin. The inhibition of ROCK activity by statins did not correlate with reductions in LDL (p = 0.57) but was associated with improvement in FMD. In conclusion, these findings provide direct clinical evidence that statins, at clinically relevant doses, could differentially inhibit ROCK activity and improve endothelial function by cholesterol-independent mechanism.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19195498      PMCID: PMC2673911          DOI: 10.1016/j.amjcard.2008.10.008

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  27 in total

Review 1.  Comparative pharmacology of rosuvastatin.

Authors:  Fergus McTaggart
Journal:  Atheroscler Suppl       Date:  2003-03       Impact factor: 3.235

2.  Increased Rho kinase activity in a Taiwanese population with metabolic syndrome.

Authors:  Ping-Yen Liu; Jyh-Hong Chen; Li-Jen Lin; James K Liao
Journal:  J Am Coll Cardiol       Date:  2007-04-02       Impact factor: 24.094

3.  Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels.

Authors:  I Jialal; D Stein; D Balis; S M Grundy; B Adams-Huet; S Devaraj
Journal:  Circulation       Date:  2001-04-17       Impact factor: 29.690

4.  HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells.

Authors:  T Bourcier; P Libby
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-02       Impact factor: 8.311

5.  Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways.

Authors:  Masato Eto; Toshiyuki Kozai; Francesco Cosentino; Hana Joch; Thomas F Lüscher
Journal:  Circulation       Date:  2002-04-16       Impact factor: 29.690

6.  Rho-kinase is involved in macrophage-mediated formation of coronary vascular lesions in pigs in vivo.

Authors:  K Miyata; H Shimokawa; T Kandabashi; T Higo; K Morishige; Y Eto; K Egashira; K Kaibuchi; A Takeshita
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-11       Impact factor: 8.311

7.  Nitric oxide-induced decrease in calcium sensitivity of resistance arteries is attributable to activation of the myosin light chain phosphatase and antagonized by the RhoA/Rho kinase pathway.

Authors:  Steffen-Sebastian Bolz; Lukas Vogel; Daniel Sollinger; Roland Derwand; Cor de Wit; Gervaise Loirand; Ulrich Pohl
Journal:  Circulation       Date:  2003-06-09       Impact factor: 29.690

8.  HMG-CoA reductase inhibitors reduce interleukin-6 synthesis in human vascular smooth muscle cells.

Authors:  Takayuki Ito; Uichi Ikeda; Masahisa Shimpo; Ruri Ohki; Masafumi Takahashi; Keiji Yamamoto; Kazuyuki Shimada
Journal:  Cardiovasc Drugs Ther       Date:  2002-03       Impact factor: 3.727

9.  Inhibition of Rho/Rho-kinase signaling downregulates plasminogen activator inhibitor-1 synthesis in cultured human monocytes.

Authors:  Toshiyuki Ishibashi; Kenji Nagata; Hiroshi Ohkawara; Takayuki Sakamoto; Keiko Yokoyama; Joji Shindo; Koichi Sugimoto; Sotaro Sakurada; Yoh Takuwa; Tamio Teramoto; Yukio Maruyama
Journal:  Biochim Biophys Acta       Date:  2002-06-12

10.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

Authors: 
Journal:  Lancet       Date:  2002-07-06       Impact factor: 79.321

View more
  22 in total

1.  Measurement of Rho-associated kinase (ROCK) activity in humans: validity of leukocyte p-MBS/t-MBS in comparison with vascular response to fasudil.

Authors:  Takaki Hata; Chikara Goto; Junko Soga; Takayuki Hidaka; Yuichi Fujii; Naomi Idei; Noritaka Fujimura; Tatsuya Maruhashi; Shinsuke Mikami; Yasuki Kihara; Kazuaki Chayama; Kensuke Noma; James K Liao; Yukihito Higashi
Journal:  Atherosclerosis       Date:  2010-10-12       Impact factor: 5.162

Review 2.  Rho kinases in cardiovascular physiology and pathophysiology: the effect of fasudil.

Authors:  Jianjian Shi; Lei Wei
Journal:  J Cardiovasc Pharmacol       Date:  2013-10       Impact factor: 3.105

Review 3.  Role of lipotoxicity in endothelial dysfunction.

Authors:  Jeong-a Kim; Monica Montagnani; Sruti Chandrasekran; Michael J Quon
Journal:  Heart Fail Clin       Date:  2012-08-10       Impact factor: 3.179

Review 4.  Effects of rosuvastatin versus atorvastatin on small dense low-density lipoprotein: a meta-analysis of randomized trials.

Authors:  Hisato Takagi; Masao Niwa; Yusuke Mizuno; Hirotaka Yamamoto; Shin-nosuke Goto; Takuya Umemoto
Journal:  Heart Vessels       Date:  2013-05-05       Impact factor: 2.037

5.  Gene variations of ROCKs and risk of ischaemic stroke: the Women's Genome Health Study.

Authors:  Robert Y L Zee; Qing-Mei Wang; Daniel I Chasman; Paul M Ridker; James K Liao
Journal:  Clin Sci (Lond)       Date:  2014-06       Impact factor: 6.124

Review 6.  Rho kinase as a therapeutic target in cardiovascular disease.

Authors:  Michelle Surma; Lei Wei; Jianjian Shi
Journal:  Future Cardiol       Date:  2011-09

Review 7.  Endothelial dysfunction in diabetes: pathogenesis, significance, and treatment.

Authors:  Sandra J Hamilton; Gerald F Watts
Journal:  Rev Diabet Stud       Date:  2013-08-10

8.  The role of Rho/Rho-kinase pathway in the expression of ICAM-1 by linoleic acid in human aortic endothelial cells.

Authors:  Chang Hee Jung; Woo Je Lee; Jenie Yoonoo Hwang; So Mi Seol; Yun Mi Kim; Yoo La Lee; Ji Hyun Ahn; Joong-Yeol Park
Journal:  Inflammation       Date:  2012-06       Impact factor: 4.092

Review 9.  Statin treatment for patients with heart failure.

Authors:  W H Wilson Tang; Gary S Francis
Journal:  Nat Rev Cardiol       Date:  2010-03-16       Impact factor: 32.419

Review 10.  Pleiotropic Effects of Statins on the Cardiovascular System.

Authors:  Adam Oesterle; Ulrich Laufs; James K Liao
Journal:  Circ Res       Date:  2017-01-06       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.